Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
17 Results for "
human TLR9
" in MedChemExpress (MCE) Product Catalog:
Products (17)
17 Results for "human TLR9" in MCE Product Catalog:
11
11 Publications Verification
Target:
Research Areas:
AT791 is a potent and orally bioavailable TLR7 and TLR9 inhibitor. AT791 inhibits TLR7 and 9 signaling in a variety of human and mouse cell types and inhibits DNA-TLR9 interaction in vitro .
2
Target:
Research Areas:
ODN 1018 (1018 ISS) is a TLR9 agonist and immune modulator. ODN 1018 exhibits adjuvant activity and augments CD8+ T cell responses with LNP-encapsulated OVA peptides. ODN 1018 triggers sustained suppression of allergic airway inflammation. ODN 1018 can be used for the research of allergic asthma and systemic lupus erythematosus .
1
1 Cited Publications
Synonyms: ODN 2006; PF-3512676; CpG 7909; ODN 7909
Agatolimod ((ODN 2006; PF-3512676; CpG 7909)) is a TLR9 agonist and immunomodulator with an EC50 of 180 nM against human TLR9. Agatolimod activates and upregulates the expression of both TLR9 and TLR6, and mediates downstream signaling pathways via IRAK4, IRF5, IRF7. Agatolimod induces Th1-type innate and adaptive immune responses, activates various immune cells and promotes antigen presentation, regulates antibody levels and immune cell infiltration, upregulates the secretion of multiple cytokines, induces apoptosis and cell cycle arrest, enhances cytotoxicity, and clears intracellular Salmonella. Agatolimod is applicable to research on COVID-19, breast cancer, lung adenocarcinoma, HPV-related tumors, melanoma, and salmonellosis .
1
1 Cited Publications
Target:
Research Areas:
TLR9-IN-1 is a potent and selective TLR9 inhibitor with an IC50 value of 7 nM for human TLR9. TLR9-IN-1 can be used for researching diseases associated with undesirable immune response .
1
1 Cited Publications
Cat. No.: HY-P991257
Target:
Research Areas:
Cat. No.: HY-150750A
Purity: 93.61%
Research Areas:
ODN M362 sodium is a TLR9 agonist that acts as a vaccine adjuvant. ODN M362 sodium activates mouse splenocytes, induces apoptosis in human hepatocellular carcinoma cells, upregulates proinflammatory cytokines in human hepatocellular carcinoma cells, and inhibits the proliferation of human hepatocellular carcinoma cells. ODN M362 sodium upregulates the expression of TLR9/TLR6, activates downstream signaling pathways via IRAK4 and IRF7, and strongly amplifies antigen-specific cellular immune responses to participate in innate immune activation. ODN M362 sodium can be used in research related to hepatocellular carcinoma and breast cancer .
Cat. No.: HY-148511
CAS No.: 147063-80-7
Synonyms: CMP-001
Research Areas:
Vidutolimod (CMP-001) is a virus-like particle containing a TLR9 activator . Vidutolimod induces human peripheral blood mononuclear cells to secrete IFNα, and upregulates the gene expression of CXCL10, PDL1, IDO and CD80. Vidutolimod activates TLR9, which in turn triggers plasmacytoid dendritic cell activation, production of IFNγ and TNFα, induction of CXCL10, and recruitment of antitumor T cells. Vidutolimod causes influenza-like symptoms, hypotension and tumor regression, and its activity depends on the presence of anti-Qβ antibodies. Vidutolimod modulates monocyte function, promotes CD4 T cell proliferation, and activates multiple immune cell types in an environment with anti-Qβ antibodies. Vidutolimod prolongs the survival of tumor-bearing mice. Vidutolimod is used in research related to advanced melanoma, head and neck squamous cell carcinoma, and advanced non-small cell lung cancer .
Cat. No.: HY-RS14599
Research Areas:
TLR9 Human Pre-designed siRNA Set A contains three designed siRNAs for TLR9 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Research Areas:
M199 is a potent TLR3/TLR9 signaling inhibitor. M199 induces secretion of IL-6, IL-8 and TNFα in human PBMCs. M199 is used as a selective inducer of the immune response .
Cat. No.: HY-150741B
Purity: 97.34%
Research Areas:
FITC-labeled ODN 2216 (sodium) is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. FITC-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.
Cat. No.: HY-150741A
Target:
Research Areas:
Biotin-labeled ODN 2216 (sodium) is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. Biotin-labeled ODN 2216 (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.
Cat. No.: HY-174519
Target:
Research Areas:
Human TLR9 mRNA encodes the human toll like receptor 9 (TLR9) protein, a member of the Toll-like receptor (TLR) family which plays a fundamental role in pathogen recognition and activation of innate immunity. TLR9 mediates cellular response to unmethylated CpG dinucleotides in bacterial DNA to mount an innate immune response.
Cat. No.: HY-162649
CAS No.: 754998-88-4
Target:
Research Areas:
TIC10g is a dual inhibitor for toll-like receptor 7 and 9 (TLR7 and TLR9), which inhibits TLR7 and TLR9 mediated TNF-α release in mouse macrophages (IC50 is 14.5 μM and 6.5 μM) and human B lymphocytes (IC50 is 7.69 μM and 11.5 μM). TIC10g inhibits the activation of NF-κB and MAPK, and exhibits anti-inflammatory activity against systemic lupus erythematosus and rheumatoid arthritis .
Cat. No.: HY-181884
CAS No.: 2903190-66-7
Research Areas:
TLR9-IN-3 is a TLR9 antagonist with an IC50 of 0.4 μM. TLR9-IN-3 shows selectivity for TLR4 and TLR8, and inhibits CD69 activation in human whole blood with a corresponding IC50 of 1.1 μM. TLR9-IN-3 can be used in research related to pulmonary fibrosis .
Cat. No.: HY-124709
CAS No.: 1351978-48-7
Research Areas:
TLR9 antagonist 2 is a highly selective and water-soluble TLR9 antagonist with an IC50 of 13 nM against human TLR9. TLR9 antagonist 2 inhibits CpG-induced production of the pro-inflammatory cytokine IL-6. TLR9 antagonist 2 is applicable for research on systemic, TLR9-mediated uncontrolled inflammatory responses, such as sepsis .
Cat. No.: HY-187531
CAS No.: 2403782-38-5
Research Areas:
TLR7/8/9 antagonist-3 is an orally active antagonist of TLR7, TLR8 and TLR9, with human IC50 values of 0.008 μM, 0.006 μM and 0.072 μM, respectively. TLR7/8/9 antagonist-3 blocks agonist-induced activation of hTLR7, hTLR8, hTLR9, mTLR7 and mTLR9, and reduces serum IFNα and TNFα levels. TLR7/8/9 antagonist-3 can be used in the research of autoimmune diseases .
Cat. No.: HY-148200A
Purity: 99.28%
Target:
Research Areas:
L2H2-6OTD diformic is a G-quadruplex (G-quadruplex, G4) ligand and telomerase (telomerase) inhibitor, with an IC50 of 15 nM against human telomerase. L2H2-6OTD diformic induces the formation of antiparallel G-quadruplex structures in long telomeric DNA. L2H2-6OTD diformic stabilizes the G4 structure of GD3 and enhances the immunological activity of CpG ODN. L2H2-6OTD diformic is applicable to research related to the development of G4-CpG immune adjuvants .
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
